Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Effect of preoperative infusion chemotherapy combined with hyperthermia on sPD-L1 and CEA levels and overall survival of elderly patients undergoing radical resection of lung cancer.
|
31128008 |
2019 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Association of neurologic manifestations and CEA levels with the diagnosis of brain metastases in lung cancer patients.
|
30903516 |
2019 |
Malignant neoplasm of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Specific driving of the suicide E gene by the CEA promoter enhances the effects of paclitaxel in lung cancer.
|
31548657 |
2019 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The significance of combined serum CEA and CA125 detection in lung cancer is confirmed.
|
30672447 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
CEA, PNI and p-stage are independent prognostic factors in elderly patients after surgery for primary lung cancer.
|
29528442 |
2018 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Detecting CTCs and tumor cells in BALF had similar areas under curves (AUC =0.871 and 0.963, respectively; P>0.05) in discriminating benign lesions from lung cancer (sensitivity 83.8% and 92.6%, specificity 86.5% and 99.9%, respectively), both of which were larger than those of NSE, CEA, and CA125 (AUC =0.564, 0.512 and 0.554, respectively; all P<0.05).
|
29780629 |
2018 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of CEA and hTERT in CTCs derived from the blood of a patient with lung cancer were also validated.
|
29435038 |
2018 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The levels of CEA and CA125 in IPF patients were much higher in IPF patients with lung cancer (P ≤ .001).
|
29094803 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multivariate logistic regression model (LRM) identified tumor size, CEA, SCC, CYFRA21-1, pro-GRP, and HE4 as independent risk factors for lung cancer.
|
29412152 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The importance of our results was that we found decreased circulating HSP70, in combination with elevated CEA and CA 19-9, could be utilized in the diagnosis of early (stage I and II) lung cancer.
|
30245753 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
|
29247745 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
CEA in combination with LDCT significantly increases the value of lung cancer screening compared with using LDCT alone particularly in participants with indeterminate baseline LDCT in both initial and 2-year screening outcomes.
|
30032839 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
At 90% specificity, the panel of MIC-1, Cyfra21-1, CA125 and CEA provided 89.5% sensitivity for early diagnosis of lung cancer, which could be used to concentrate the high-risk subjects for further LDCT screening.
|
28514755 |
2017 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
CEA, a lung cancer protein biomarker, was used as analyte to demonstrate the principle of the immunochromatographic assay on cotton thread biosensor.
|
28411630 |
2017 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we analyzed the serum levels of six tumor markers (CEA, CYFRA21-1, SCC, NSE, ProGRP, and CA125) in 2097 suspected patients with lung cancer and determined whether the combination of the tumor markers was useful for histological diagnosis of lung cancer.
|
28607926 |
2017 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
A classification rule based on EGF, sCD26, Calprotectin and CEA was established, able to reasonably discriminate lung cancer with 97% sensitivity and 43% specificity in the training set, and 91.7% sensitivity and 45.4% specificity in the validation set.
|
28117344 |
2017 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Enhanced antitumor effect of combining TRAIL and MnSOD mediated by CEA-controlled oncolytic adenovirus in lung cancer.
|
27080225 |
2016 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Analysis of CEA expression and EGFR mutation status in non-small cell lung cancers.
|
24870738 |
2014 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Two tests in lung cancer (ERCC1 and EGFR) and 1 test in breast cancer (CEA/CA15-3/CA27.29) were identified as top research priorities.
|
22274803 |
2012 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phospholipases release CEA from tumor cells resulting in high circulating serum levels of soluble CEA (sCEA) that has been validated as marker for progression of colorectal, breast, and lung cancers. sCEA also acts as a competitive inhibitor for anticancer strategies targeting membrane-bound CEA.
|
19342971 |
2009 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
CEA content in non-carcinomatous lung tissue was increased in smokers with emphysema (mean (SD) 38.0 (9.2) ng/mg protein) or with lung cancer (38.2 (21.6)) compared with non-smokers (11.0 (5.4)) or ex-smokers (5.9 (2.2)).
|
7638808 |
1995 |